Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

This study has been completed.
Information provided by:
Callisto Pharmaceuticals Identifier:
First received: June 28, 2004
Last updated: December 20, 2007
Last verified: December 2007
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2007
  Estimated Primary Completion Date: No date given